Please enable JavaScript to continue using this application.

Compare $LRMR vs $SABS | Chartloom

Compare

$LRMR vs $SABS

Larimar Therapeutics Inc · SAB Biotherapeutics Inc

LRMR

Larimar Therapeutics Inc

SABS

SAB Biotherapeutics Inc

Compare $LRMR vs $SABS

Comparing Larimar Therapeutics Inc and SAB Biotherapeutics Inc

LRMRLarimar Therapeutics Inc

SABSSAB Biotherapeutics Inc

LRMRLarimar Therapeutics Inc

Market cap

$277M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-23.1%

52W performance

-44.6%

FCF yield

-56.3%

SABSSAB Biotherapeutics Inc

Market cap

$228M

P/E (TTM)

20.43x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-21.0%

52W performance

27.4%

FCF yield

-25.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LRMR

SABS

Detailed metrics comparison

LRMR

Larimar Therapeutics Inc

SABS

SAB Biotherapeutics Inc

Market Cap

LRMR$277M

SABS$228M

Enterprise Value

LRMR$185M

SABS$223M

Price

LRMR$2.67

SABS$2.98

P/E Ratio

LRMRN/A

SABS20.43x

P/S Ratio

LRMR0.00x

SABS204.97x

EV/Sales

LRMR0.00x

SABS201.14x

EV/EBITDA

LRMR0.00x

SABS0.00x

P/B Ratio

LRMR2.41x

SABS1.26x

P/FCF Ratio

LRMRN/A

SABSN/A

EV/FCF

LRMR-1.18x

SABS-3.88x

PEG Ratio

LRMRN/A

SABSN/A

Forward P/E (NTM)

LRMRN/A

SABSN/A

Forward P/S (NTM)

LRMRN/A

SABSN/A

Revenue (TTM)

LRMR$0

SABS$0

Revenue Growth (YoY)

LRMRN/A

SABSN/A

Forward Rev Growth

LRMR290.4%

SABS13369.8%

Gross Margin (TTM)

LRMR0.0%

SABS0.0%

Operating Margin (TTM)

LRMR0.0%

SABS0.0%

EBITDA Margin (TTM)

LRMR0.0%

SABS0.0%

Net Margin (TTM)

LRMR0.0%

SABS0.0%

FCF Margin (TTM)

LRMRN/A

SABSN/A

Net Income (TTM)

LRMR$-173M

SABS$2M

FCF (TTM)

LRMR$-156M

SABS$-57M

EPS (TTM)

LRMR-$1.66

SABS$0.00

ROE (TTM)

LRMR-13739.0%

SABS15.2%

ROA (TTM)

LRMR-9765.0%

SABS12.5%

ROIC (TTM)

LRMR-13739.0%

SABS14.6%

Cash

LRMR$93M

SABS$8M

Debt

LRMR$0

SABS$3M

Net Cash/Debt

LRMR$93M

SABS$5M

Current Ratio (TTM)

LRMR4.70x

SABS9.22x

Quick Ratio (TTM)

LRMR4.58x

SABS8.93x

Debt/Equity (TTM)

LRMR0.00x

SABS0.01x

Debt/Assets (TTM)

LRMR0.0%

SABS0.0%

Interest Coverage (TTM)

LRMRN/A

SABSN/A

Net Debt/EBITDA (TTM)

LRMR0.00x

SABS0.00x

Beta

LRMR0.68

SABS0.80

52W Performance

LRMR-44.6%

SABS27.4%

YTD Performance

LRMR-23.1%

SABS-21.0%

% from 52W High

LRMR-58.4%

SABS-42.1%

% from 52W Low

LRMR2.3%

SABS41.9%

Asset Turnover (TTM)

LRMR0.00x

SABS0.02x

FCF Yield (TTM)

LRMR-56.3%

SABS-25.2%

Earnings Yield (TTM)

LRMR-62.2%

SABS1.1%

Dividend Yield (TTM)

LRMRN/A

SABSN/A

Rule of 40

LRMR0.0

SABS0.0

EV/GP/RG

LRMRN/A

SABSN/A

Ticker research

View LRMR research View SABS research

Metric	LRMR Larimar Therapeutics Inc	SABS SAB Biotherapeutics Inc
Market & Valuation
Market Cap	$277M	$228M
Enterprise Value	$185M	$223M
Price	$2.67	$2.98
P/E Ratio	N/A	20.43x
P/S Ratio	0.00x	204.97x
EV/Sales	0.00x	201.14x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.41x	1.26x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.18x	-3.88x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	290.4%	13369.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-173M	$2M
FCF (TTM)	$-156M	$-57M
EPS (TTM)	-$1.66	$0.00
ROE (TTM)	-13739.0%	15.2%
ROA (TTM)	-9765.0%	12.5%
ROIC (TTM)	-13739.0%	14.6%
Financial Health
Cash	$93M	$8M
Debt	$0	$3M
Net Cash/Debt	$93M	$5M
Current Ratio (TTM)	4.70x	9.22x
Quick Ratio (TTM)	4.58x	8.93x
Debt/Equity (TTM)	0.00x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.68	0.80
52W Performance	-44.6%	27.4%
YTD Performance	-23.1%	-21.0%
% from 52W High	-58.4%	-42.1%
% from 52W Low	2.3%	41.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-56.3%	-25.2%
Earnings Yield (TTM)	-62.2%	1.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View LRMR research	View SABS research

Valuation

P/E Ratio

SABS

20.43x

P/S Ratio

LRMR

0.00x

SABS

204.97x

EV/FCF

SABS

-3.88x

LRMR

-1.18x

Growth & revenue

Forward Revenue Growth

SABS

13369.8%

LRMR

290.4%

Profitability & performance

Gross Margin

LRMR

0.0%

SABS

0.0%

ROE

SABS

15.2%

LRMR

-13739.0%

FCF Yield %

SABS

-25.2%

LRMR

-56.3%

52-Week Performance

SABS

27.4%

LRMR

-44.6%

Detailed metrics comparison

LRMR

Larimar Therapeutics Inc

SABS

SAB Biotherapeutics Inc

Market Cap

LRMR$277M

SABS$228M

Enterprise Value

LRMR$185M

SABS$223M

Price

LRMR$2.67

SABS$2.98

P/E Ratio

LRMRN/A

SABS20.43x

P/S Ratio

LRMR0.00x

SABS204.97x

EV/Sales

LRMR0.00x

SABS201.14x

EV/EBITDA

LRMR0.00x

SABS0.00x

P/B Ratio

LRMR2.41x

SABS1.26x

P/FCF Ratio

LRMRN/A

SABSN/A

EV/FCF

LRMR-1.18x

SABS-3.88x

PEG Ratio

LRMRN/A

SABSN/A

Forward P/E (NTM)

LRMRN/A

SABSN/A

Forward P/S (NTM)

LRMRN/A

SABSN/A

Revenue (TTM)

LRMR$0

SABS$0

Revenue Growth (YoY)

LRMRN/A

SABSN/A

Forward Rev Growth

LRMR290.4%

SABS13369.8%

Gross Margin (TTM)

LRMR0.0%

SABS0.0%

Operating Margin (TTM)

LRMR0.0%

SABS0.0%

EBITDA Margin (TTM)

LRMR0.0%

SABS0.0%

Net Margin (TTM)

LRMR0.0%

SABS0.0%

FCF Margin (TTM)

LRMRN/A

SABSN/A

Net Income (TTM)

LRMR$-173M

SABS$2M

FCF (TTM)

LRMR$-156M

SABS$-57M

EPS (TTM)

LRMR-$1.66

SABS$0.00

ROE (TTM)

LRMR-13739.0%

SABS15.2%

ROA (TTM)

LRMR-9765.0%

SABS12.5%

ROIC (TTM)

LRMR-13739.0%

SABS14.6%

Cash

LRMR$93M

SABS$8M

Debt

LRMR$0

SABS$3M

Net Cash/Debt

LRMR$93M

SABS$5M

Current Ratio (TTM)

LRMR4.70x

SABS9.22x

Quick Ratio (TTM)

LRMR4.58x

SABS8.93x

Debt/Equity (TTM)

LRMR0.00x

SABS0.01x

Debt/Assets (TTM)

LRMR0.0%

SABS0.0%

Interest Coverage (TTM)

LRMRN/A

SABSN/A

Net Debt/EBITDA (TTM)

LRMR0.00x

SABS0.00x

Beta

LRMR0.68

SABS0.80

52W Performance

LRMR-44.6%

SABS27.4%

YTD Performance

LRMR-23.1%

SABS-21.0%

% from 52W High

LRMR-58.4%

SABS-42.1%

% from 52W Low

LRMR2.3%

SABS41.9%

Asset Turnover (TTM)

LRMR0.00x

SABS0.02x

FCF Yield (TTM)

LRMR-56.3%

SABS-25.2%

Earnings Yield (TTM)

LRMR-62.2%

SABS1.1%

Dividend Yield (TTM)

LRMRN/A

SABSN/A

Rule of 40

LRMR0.0

SABS0.0

EV/GP/RG

LRMRN/A

SABSN/A

Ticker research

View LRMR research View SABS research

Metric	LRMR Larimar Therapeutics Inc	SABS SAB Biotherapeutics Inc
Market & Valuation
Market Cap	$277M	$228M
Enterprise Value	$185M	$223M
Price	$2.67	$2.98
P/E Ratio	N/A	20.43x
P/S Ratio	0.00x	204.97x
EV/Sales	0.00x	201.14x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.41x	1.26x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.18x	-3.88x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	290.4%	13369.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-173M	$2M
FCF (TTM)	$-156M	$-57M
EPS (TTM)	-$1.66	$0.00
ROE (TTM)	-13739.0%	15.2%
ROA (TTM)	-9765.0%	12.5%
ROIC (TTM)	-13739.0%	14.6%
Financial Health
Cash	$93M	$8M
Debt	$0	$3M
Net Cash/Debt	$93M	$5M
Current Ratio (TTM)	4.70x	9.22x
Quick Ratio (TTM)	4.58x	8.93x
Debt/Equity (TTM)	0.00x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.68	0.80
52W Performance	-44.6%	27.4%
YTD Performance	-23.1%	-21.0%
% from 52W High	-58.4%	-42.1%
% from 52W Low	2.3%	41.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-56.3%	-25.2%
Earnings Yield (TTM)	-62.2%	1.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View LRMR research	View SABS research